Research comparison
Semaglutide vs Tirzepatide: research comparison
Semaglutide and tirzepatide are widely cited incretin-pathway research compounds. Neither is currently a BioLabs Research catalog SKU. This page compares published chemical identities for laboratory orientation and links PubChem/CAS records. No human benefit claims and no dosing guidance appear here.
For an on-catalog multi-agonist research reagent in a related literature space, see R3TA (retatrutide) — a distinct chemical entity (CAS 2381089-83-2) — only when your protocol specifically calls for that identity.
Quick comparison
| Field | First | Second |
|---|---|---|
| CAS | 910463-68-2 | 2023788-19-2 |
| Public formula | C187H291N45O59 | C225H348N48O68 |
| Approx. MW | ~4113.6 Da | ~4813.5 Da |
| Pathway framing (literature) | GLP-1 receptor agonist analogue | GIP / GLP-1 dual agonist |
| Catalog on this site | Not listed | Not listed |
Semaglutide
Semaglutide (CAS 910463-68-2) is a long-acting GLP-1 receptor agonist analogue documented in public chemistry databases with formula C187H291N45O59. Research use of the named substance requires verifying salt form, purity method, and peptide content on the supplier COA. PubChem provides structure and synonym cross-references for registry hygiene.
Because BioLabs Research does not list semaglutide, treat external suppliers’ paperwork as primary. Do not substitute a different incretin agonist SKU without confirming receptor pharmacology required by the assay.
Tirzepatide
Tirzepatide (CAS 2023788-19-2) is described in public records as a dual GIP and GLP-1 receptor agonist with a larger peptide backbone (formula C225H348N48O68). Identity checks should include CAS, sequence/structure file, and analytical method. It is not interchangeable with semaglutide or with triple agonists such as retatrutide.
On-catalog adjacent identity (different molecule): R3TA / retatrutide and retatrutide metabolic research notes.
Key differences
- Different CAS numbers and molecular formulas.
- Semaglutide is framed as a GLP-1 analogue; tirzepatide as dual GIP/GLP-1.
- Neither is a BioLabs catalog SKU at publish time.
- Retatrutide (R3TA) is a separate triple-agonist identity if protocols require it.
- Never infer purity from PubChem — use lot COA.
Which for which research context
Semaglutide identity when the method cites CAS 910463-68-2 or the published semaglutide structure.
Tirzepatide identity when the method cites CAS 2023788-19-2 or dual GIP/GLP-1 pharmacology specific to tirzepatide.
R3TA (retatrutide) only when the protocol names that triple agonist (CAS 2381089-83-2) — not as a silent substitute.
References
- Semaglutide: PubChem CID 56843331 · CAS 910463-68-2
- Tirzepatide: PubChem CID 156588324 · CAS 2023788-19-2
- Retatrutide (catalog): CAS 2381089-83-2 · product page
All discussion on this page is limited to chemical identity, public registry identifiers, and laboratory research framing. BioLabs Research lists reagents for in-vitro and analytical work only. Confirm vial strengths and any hosted COA PDFs on the product page or in the COA Library.
Use the solution dilution calculator and unit converter for lab math only. Related reading: blog, Science, reading a COA, Shipping.
Incretin research reagents are often high molecular weight peptides; analytical methods (HPLC area %, net peptide content) should be read carefully — see HPLC area percent vs net peptide content when that post is relevant to your QA workflow.
Keep procurement language matching the CAS on the PO line to avoid shipping the wrong analogue family.
For laboratory research use only. Not for human or veterinary use. No medical claims; no human dosing guidance.